GlassScriptPhysician profile
Tina Clements
NPI 1124018080
$26,236.50
in general payments reported to CMS, 2019-2025
66 companies · $5,808 in 2025
The $5,808 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $3,754 · 2022: $3,622 · 2023: $9,134 · 2024: $3,918 · 2025: $5,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $4,513 · Travel and Lodging: $1,678 · Honoraria: $1,170 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,299.50 |
| Consulting Fee | $4,512.50 |
| Travel and Lodging | $1,678.11 |
| Honoraria | $1,170.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $4,174.68 | 2021-2024 | Mavenclad, Mavenclad |
| Mdd US Operations, LLC | $2,249.09 | 2021-2025 | Gocovri, Gocovri |
| Tanabe Pharma America, INC. | $1,578.77 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,392.26 | 2021-2025 | |
| Abbvie INC. | $1,388.10 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,177.19 | 2021-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $1,150.21 | 2021-2024 | Austedo Xr, Ajovy, Austedo |
| Abbott Laboratories | $1,091.51 | 2021-2025 | Infinity, Proclaim |
| Tg Therapeutics, INC. | $1,023.61 | 2023-2025 | |
| Biogen, INC. | $996.39 | 2021-2025 | Tysabri, Vumerity, Tecfidera |
| Genzyme Corporation | $932.93 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $643.04 | 2021-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $617.34 | 2021-2024 | Ingrezza, Ongentys |
| Genentech USA, INC. | $617.11 | 2021-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Celgene Corporation | $518.40 | 2021-2025 | Zeposia |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $485.07 | 2021-2024 | Acthar |
| Lilly USA, LLC | $478.63 | 2022-2025 | Kisunla, Emgality, Amyvid |
| Ucb, INC. | $459.22 | 2021-2024 | Briviact, Nayzilam, Rystiggo |
| Horizon Therapeutics Plc | $447.95 | 2021-2023 | Uplizna |
| Pfizer INC. | $443.23 | 2023-2025 | |
| Amgen INC. | $357.21 | 2021-2024 | Uplizna, Aimovig |
| Argenx US, INC. | $352.27 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $283.79 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $235.95 | 2021-2023 | Rytary |
| Jazz Pharmaceuticals INC. | $233.92 | 2022-2024 | |
| Eisai INC. | $227.84 | 2021-2025 | |
| Axsome Therapeutics, INC. | $177.76 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $162.95 | 2021-2024 | Zeposia |
| Kyowa Kirin, INC. | $157.13 | 2021-2024 | Nourianz |
| Grifols USA, LLC | $151.24 | 2022-2024 | Gamunex-C |
| Boston Scientific Corporation | $141.57 | 2025 | Watchman Flx |
| Medtronic, INC. | $132.65 | 2023-2025 | Percept PC Brainsense, Sensight, Intellis Adaptivestim |
| Ipsen Biopharmaceuticals, INC | $132.52 | 2025 | Iqirvo |
| Lundbeck LLC | $130.75 | 2021-2025 | Vyepti |
| Ge Healthcare | $104.85 | 2021-2023 | |
| Ani Pharmaceuticals, INC. | $97.30 | 2023-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $92.42 | 2023 | Gammagard |
| Livanova USA, INC. | $89.74 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceutical Holding Company LTD. | $83.49 | 2022 | |
| Supernus Pharmaceuticals, INC. | $81.91 | 2021-2023 | |
| Inspire Medical Systems, INC. | $80.95 | 2025 | Inspire |
| Insightec,INC | $74.53 | 2023-2024 | Exablate |
| Glaxosmithkline, LLC. | $65.68 | 2025 | Benlysta |
| Grt US Holding, INC. | $58.96 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $56.13 | 2022-2025 | Xeomin |
| Biohaven Pharmaceuticals, INC. | $54.05 | 2021 | |
| Vanda Pharmaceuticals INC. | $52.88 | 2025 | Ponvory |
| Acorda Therapeutics, INC | $46.37 | 2023-2024 | Ampyra, Inbrija |
| Sumitomo Pharma America, INC. | $46.15 | 2023-2024 | Aptiom |
| Janssen Pharmaceuticals, INC | $41.22 | 2021-2022 | |
| Janssen Biotech, INC. | $38.27 | 2025 | |
| Alnylam Pharmaceuticals INC. | $37.40 | 2024 | Onpattro |
| Octapharma USA, INC. | $33.80 | 2022-2023 | Panzyga |
| Azurity Pharmaceuticals, INC. | $33.72 | 2024 | Horizant |
| Saluda Medical Americas, INC. | $27.45 | 2023 | Evoke Scs |
| Upsher-Smith Laboratories LLC | $24.27 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.46 | 2021 | |
| Averitas Pharma INC. | $22.09 | 2023 | Qutenza |
| Adamas Pharmaceuticals, INC. | $21.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.00 | 2024 | Nuedexta |
| Idorsia Pharmaceuticals US INC | $20.16 | 2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $19.77 | 2021 | |
| Impel Pharmaceuticals INC. | $16.78 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $14.38 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $13.83 | 2023 | Spritam |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,086.64 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.